Guess which ASX 200 tech stock was just upgraded to a buy rating

Bell Potter has turned bullish on this name this week.

Key points
  • Bell Potter sees the recent pullback in Pro Medicus shares as an opportunity, noting that despite a quieter start to FY26, significant installations, such as the Trinity contract, will drive ARR growth.
  • The broker remains positive on Pro Medicus, highlighting ongoing implementations and long-term contracts that secure approximately 90% of revenues, justifying a buy upgrade with a $320.00 target.
  • Pro Medicus is projected for 38% EPS growth in FY26, and although its shares are down 25% from their peak, Bell Potter anticipates potential upside with upcoming catalysts like the RSNA trade show.

Pro Medicus Ltd (ASX: PME) shares may be up strongly over the past 12 months, but they have pulled back meaningfully from recent highs.

While this is disappointing, the team at Bell Potter thinks that it could have created an opportunity for investors to buy into this high-quality ASX 200 tech stock.

A smiling woman holds a Facebook like sign above her head.

Image source: Getty Images

What is Bell Potter saying?

Bell Potter notes that it has been a quiet period for Pro Medicus, but it doesn't think investors should be concerned by this. It said:

The first 4 months of FY26 has seen PME announce three major deals in the US. This compares to just one (announcement) in the corresponding period for FY25, followed by a frenzy of 6 new contract announcements over the remainder of the fiscal year. We consider the quieter period for new contract announcements for the first 4 months of FY26 is not unusual, meanwhile contract implementations continue.

The broker also highlights that the ASX 200 tech stock has been very busy completing a number of installations, which will drive annualised recurring revenue (ARR) growth. It adds:

In the period since the company's FY25 result announcement in August, it has completed numerous instals which include the first and largest cohort of the Trinity contract – live in recent days, in addition to Lucid Health (live in September) and the upgrade to FMOLHS. The Trinity 'Go Live' was the largest single Big Bang transition in recent history. The 2nd and 3rd cohorts are expected in mid and late CY2026. Once fully implemented we expect Trinity will add ~$30m in ARR in addition to becoming another flagship site for implementation across a very large, multi-site IDN.

Buy the dip

Overall, Bell Potter remains very positive on the ASX tech stock and sees plenty of value in Pro Medicus shares. As a result, it has upgraded its shares to a buy rating with a $320.00 price target.

Based on its current share price of $254.90, this implies potential upside of 26% for investors over the next 12 months.

Commenting on its upgrade, the broker said:

The recurring nature of exam and baseline revenues (largely from Australia) contribute ~90% of forecast revenues, all of which is subject to long term contracts and or minimum volumes at fixed rates. The frenetic pace of implementations has continued in recent months, therefore, we anticipate professional services (including data migration) in the current half should be close to 2H25 levels.

With earnings transparency remaining high, we attribute the recent sell off to profit taking following the string of new contract wins and record earnings in FY25. Consensus EPS is for FY26 is ~152cps representing ~38% growth. While PME remains expensive relative to peers, it is now trading 25% below its all-time high (achieved in July 2025). Catalysts include the RSNA trade show in late November which represents the major selling event of the year. In addition, we expect high profile renewals over the next 1 – 2 years from the likes of Yale New Haven and Mayo clinic. We upgrade our recommendation from Hold to Buy and maintain our target price at $320.00.

Motley Fool contributor James Mickleboro has positions in Pro Medicus. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Technology Shares

A geeky-looking young man with glasses bites down onto a computer keyboard in frustration or despair.
ASX Share Market News

Tech shares led the ASX 200 amid NVIDIA scandal and Microsoft outage last week

Xero's 1H FY27 results and a strong lead from Wall Street pushed the tech sector higher.

Read more »

A woman in a red dress holding up a red graph.
Technology Shares

I went looking for shares which could double by 2030. These 3 made my shortlist

All of these shares are in recovery mode.

Read more »

Man looking at digital holograms of graphs, charts, and data.
Technology Shares

Why experts think this ASX tech share is a compelling buy today

Experts are bullish about the prospects of this technology business.

Read more »

Businessman at his desk, looking seriously at information on his digital tablet.
Technology Shares

Xero just announced a $1 billion share buyback. Would I buy now?

Management has made a big statement about the share price, but I'm more interested in what the results reveal about…

Read more »

Man with backpack spreading his arms out and soaking in the sun.
Technology Shares

Up 53% in 6 weeks. Could WiseTech shares double from here?

The ASX tech shares are up another 1.5% on Thursday morning.

Read more »

Shocked woman reacts to news on her computer.
Technology Shares

Why are Xero shares flying 12% higher today?

Find out why investors are flocking to the stock today.

Read more »

A boy bounds after a big colourful bouncing ball in a grassy field.
Technology Shares

Life360 shares rebound 9% on Wednesday. What on earth is going on with the ASX tech stock this week?

The shares are storming higher again today.

Read more »

Happy woman working on a laptop.
Technology Shares

Why these are 3 of my favourite ASX tech shares to buy

I've been looking at three companies with strong positions in their markets and opportunities to become much bigger.

Read more »